Skip to main contentAI and Advanced
/
LASA · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
LA
NSE · Equity shares · Biotechnology & Drugs0.13 · -4.86%
Lasa Supergenerics LASA
NSE:INR 7.2
BSE:INR 6.27
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for LASA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 7.07
Day rangeINR 6.45 — INR 6.71
52-week rangeINR 5.65 — INR 14.14
Volume46,912
Market cap36.32
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)25.14
Net Income (INR Cr)-34.09
Rev Growth (5 Year %)-34.11
Book Value6.58
EPS-4.07
Price/BV1.09Computed
Research path: Interpret Lasa Supergenerics's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
LASALasa Supergenerics1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 66.27 | 101.53 | 150.87 |
| Cash Equivalents | 0.41 | 0.52 | 0.89 |
| Other Liabilities Total | 0.17 | 0.44 | 0.47 |
| Common Stock Total | 50.1 | 50.1 | 50.1 |
| Other Current Assets Total | 7.88 | 5.73 | 0.05 |
| Total Assets | 66.27 | 101.53 | 150.87 |
| Current Portof LT Debt/Capital Leases | 9.75 | 2.13 | 22.08 |
| Cash | 0.29 | 0.28 | 0.61 |
| Total Equity | 49.62 | 83.71 | 96.68 |
| Retained Earnings(Accumulated Deficit) | -0.48 | -8.36 | 4.6 |
| Total Common Shares Outstanding | 5.01 | 5.01 | 5.01 |
| Tangible Book Valueper Share Common Eq | 6.58 | 12.74 | 14.12 |
| Total Liabilities | 16.65 | 17.82 | 54.19 |
| Total Debt | 9.75 | 2.13 | 22.08 |
| Cashand Short Term Investments | 0.7 | 0.79 | 1.5 |
| Total Receivables Net | 0.04 | 1.49 | 7.19 |
| Deferred Income Tax | -0.3 | 0.22 | 4.85 |
| Accounts Receivable-Trade Net | 0.04 | 1.49 | 3.59 |
| Property/Plant/Equipment Total-Net | 38.38 | 48.34 | 86.33 |
| Total Current Liabilities | 16.77 | 17.15 | 48.87 |
| Total Inventory | 1.82 | 24.5 | 29.1 |
| Accounts Payable | 2.12 | 10.22 | 14.05 |
| Other Currentliabilities Total | 4.9 | 4.81 | 12.01 |
| Intangibles Net | 16.67 | 8.83 | 14.26 |
| Other Long Term Assets Total | 0.78 | 0.78 | 0.71 |
| Total Current Assets | 10.44 | 32.51 | 37.89 |
| Accumulated Depreciation Total | Not available | -45.92 | -112.33 |
| Long Term Debt | Not available | 0 | 0 |
| Additional Paid-In Capital | Not available | 41.98 | 41.98 |
| Property/Plant/Equipment Total-Gross | Not available | 94.02 | 196.15 |
| Goodwill Net | Not available | 11.07 | 11.68 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Total Long Term Debt | Not available | 0 | 0 |
| Accrued Expenses | Not available | Not available | 0.73 |
| Prepaid Expenses | Not available | Not available | 0.06 |
Fundamentals
Valuation and ratios
Margins
Operating Margin 12m-136.2
Operating Margin 5y Avg-21.72
Net Profit Margin 12m-134.89
Net Profit Margin 5y-21.26
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio1.44
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk45.99
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.3 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,375 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,972.65 | 1.68 L | 72.73 | — |
| Cipla | INR 1,406 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,119 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 53.65%
- FII
- 0.47%
- Other
- 46.35%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Price to sales forward of Lasa Supergenerics Ltd. – BSE:LASA - TradingViewMarket news · 13 Jul 2026, 5:26 am
Price to sales forward of Lasa Supergenerics Ltd. – BSE:LASA TradingView
Lasa Supergenerics Ltd is Rated Strong Sell - MarketsMojoMarket news · 2 Jul 2026, 10:38 am
Lasa Supergenerics Ltd is Rated Strong Sell MarketsMojo
Enterprise value to revenue forward of Lasa Supergenerics Ltd. – NSE:LASA - TradingViewMarket news · 26 Jun 2026, 9:43 am
Enterprise value to revenue forward of Lasa Supergenerics Ltd. – NSE:LASA TradingView
Lasa Supergenerics promoter reports no new encumbrance in FY26 - scanx.tradeMarket news · 3 Jun 2026, 5:27 am
Lasa Supergenerics promoter reports no new encumbrance in FY26 scanx.trade
Lasa Supergenerics Ltd Locks at Lower Circuit With 3.7% Loss — Sellers Queue, No Buyers in Sight - Markets MojoMarket news · 1 Jun 2026, 12:00 pm
Lasa Supergenerics Ltd Locks at Lower Circuit With 3.7% Loss — Sellers Queue, No Buyers in Sight Markets Mojo
Lasa Supergenerics Q4 FY26: Revenue Collapse Signals Critical Operational Crisis - Markets MojoMarket news · 31 May 2026, 5:05 pm
Lasa Supergenerics Q4 FY26: Revenue Collapse Signals Critical Operational Crisis Markets Mojo
Corporate actions
Events
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board Meetings(Revised)
- board MeetingsAudited Results
Rusaka Markets Community
Discussion and sentiment for Lasa Supergenerics
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and others. It specializes in catalyst chemistry and manufactures anthelmintic/ veterinary API products with production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located in Chiplun, Maharashtra.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- LASA
- BSE Code
- 540702
Questions
Stock FAQ
What is the symbol and ISIN of Lasa Supergenerics?
Lasa Supergenerics has the symbol LASA and ISIN - INE670X01014.
What is the current price of Lasa Supergenerics?
Lasa Supergenerics is currently trading at INR 7.20.
What are the year high and year low of Lasa Supergenerics?
Lasa Supergenerics has a year high of INR 14.14 and a year low of INR 5.65.
What is the market capitalization of Lasa Supergenerics?
Lasa Supergenerics has a market capitalization of INR 36.32 crore.
What is the P/E ratio of Lasa Supergenerics?
Lasa Supergenerics has a P/E ratio of NA.
What is the dividend yield of Lasa Supergenerics?
Lasa Supergenerics has a dividend yield of 0.00%.
How is the financial performance of Lasa Supergenerics based on revenue, net income, and EPS?
Lasa Supergenerics has revenue of INR 25.14 crore, net income of INR -34.09 crore, and EPS of INR -4.08.
What is the book value of Lasa Supergenerics?
Lasa Supergenerics has a book value of INR 6.58.
What is the debt-to-equity ratio of Lasa Supergenerics?
Lasa Supergenerics has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Lasa Supergenerics?
Lasa Supergenerics has a price-to-book ratio of 1.09 and a price-to-sales ratio of 1.44.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.